These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 24621652)

  • 1. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
    Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
    J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy.
    Grune J; Benz V; Brix S; Salatzki J; Blumrich A; Höft B; Klopfleisch R; Foryst-Ludwig A; Kolkhof P; Kintscher U
    J Cardiovasc Pharmacol; 2016 May; 67(5):402-11. PubMed ID: 26859196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.
    Grune J; Beyhoff N; Smeir E; Chudek R; Blumrich A; Ban Z; Brix S; Betz IR; Schupp M; Foryst-Ludwig A; Klopfleisch R; Stawowy P; Houtman R; Kolkhof P; Kintscher U
    Hypertension; 2018 Apr; 71(4):599-608. PubMed ID: 29437893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
    Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
    J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
    Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
    Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
    Arai K; Tsuruoka H; Homma T
    Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
    Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
    Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
    Sato N; Ajioka M; Yamada T; Kato M; Myoishi M; Yamada T; Kim SY; Nowack C; Kolkhof P; Shiga T;
    Circ J; 2016 Apr; 80(5):1113-22. PubMed ID: 27074824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
    Bamberg K; Johansson U; Edman K; William-Olsson L; Myhre S; Gunnarsson A; Geschwindner S; Aagaard A; Björnson Granqvist A; Jaisser F; Huang Y; Granberg KL; Jansson-Löfmark R; Hartleib-Geschwindner J
    PLoS One; 2018; 13(2):e0193380. PubMed ID: 29474466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction.
    Lachaux M; Barrera-Chimal J; Nicol L; Rémy-Jouet I; Renet S; Dumesnil A; Wecker D; Richard V; Kolkhof P; Jaisser F; Ouvrard-Pascaud A; Mulder P
    Diabetes Obes Metab; 2018 Oct; 20(10):2399-2407. PubMed ID: 29862614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
    Filippatos G; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Kim SY; Nowack C; Palombo G; Kolkhof P; Kimmeskamp-Kirschbaum N; Pieper A; Pitt B
    Eur Heart J; 2016 Jul; 37(27):2105-14. PubMed ID: 27130705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling.
    Lavall D; Jacobs N; Mahfoud F; Kolkhof P; Böhm M; Laufs U
    Biochem Pharmacol; 2019 Oct; 168():173-183. PubMed ID: 31283930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
    Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
    Amazit L; Le Billan F; Kolkhof P; Lamribet K; Viengchareun S; Fay MR; Khan JA; Hillisch A; Lombès M; Rafestin-Oblin ME; Fagart J
    J Biol Chem; 2015 Sep; 290(36):21876-89. PubMed ID: 26203193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin system blockade: Finerenone.
    Ruilope LM; Tamargo J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S47-S53. PubMed ID: 28577743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
    Lima-Posada I; Stephan Y; Soulié M; Palacios-Ramirez R; Bonnard B; Nicol L; Kolkhof P; Jaisser F; Mulder P
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.
    Lattenist L; Lechner SM; Messaoudi S; Le Mercier A; El Moghrabi S; Prince S; Bobadilla NA; Kolkhof P; Jaisser F; Barrera-Chimal J
    Hypertension; 2017 May; 69(5):870-878. PubMed ID: 28320854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
    Kolkhof P; Hartmann E; Freyberger A; Pavkovic M; Mathar I; Sandner P; Droebner K; Joseph A; Hüser J; Eitner F
    Am J Nephrol; 2021; 52(8):642-652. PubMed ID: 34111864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.